期刊
CA-A CANCER JOURNAL FOR CLINICIANS
卷 62, 期 3, 页码 147-172出版社
WILEY
DOI: 10.3322/caac.21139
关键词
-
类别
资金
- Qiagen
- Roche
- Gen-Probe, Inc
- BD
- Abbott Laboratories
- Roche Molecular Systems
- Merck, Inc
- GlaxoSmithKline (GSK), Inc.
- National Institute of Allergy and Infectious Diseases
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, and a recent symposium cosponsored by the ACS, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, which was attended by 25 organizations. The new screening recommendations address age-appropriate screening strategies, including the use of cytology and high-risk human papillomavirus (HPV) testing, follow-up (eg, the management of screen positives and screening intervals for screen negatives) of women after screening, the age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16 and HPV18 infections. CA Cancer J Clin 2012. (C) 2012 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据